ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For HER-2-positive LABC, anthracyclines should not be administered concurrently with trastuzumab since this approach does not increase the pCR rate, and it could increase the risk of cardiac toxicity, based largely on studies in the metastatic setting [35,36].”
BackgroundSelf-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“lapatinib plus capecitabine in the subset of 118 patients who were randomized in the first-line setting, having relapsed on or within 6 months of adjuvant trastuzumab, appeared similar to the effect seen in the overall trial [100].”
BackgroundResultSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The mTOR inhibitor everolimus when added to exemestane, in patients progressing on non-steroidal aromatase inhibitor, provided a significant PFS prolongation of about 5 months [89,90].”
BackgroundSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“Table 1 describes the grading system used [15].”
MethodCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
ResultSelf-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Research works printed but not linked: 2
- Handesman D Androgen Actions and Pharmacologic Uses, Endocrinology 2001 Philadelphia WB Saunders 2232 2242
- Wildiers H Kim SB Gonzalez-Martin A T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice 2013 Presented at the European Cancer Congress September 27–October 1 Amsterdam, The Netherlands (abstr LBA15)
Cited by
Items 401–500 of 540
Radiothérapie des cancers du sein inflammatoires
Jardel, P., Alami, Z., Vignot, S., Creisson, A., Danhier, S., Geffrelot, J., Lévy, C., Kammerer, E., Lebrun, J., & Thariat, J. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.12.008 · Cited by 4
BHARGAVA, P. G., Rathnasamy, N., Shenoy, R., Gulia, S., Bajpai, J., Ghosh, J., Rath, S., Budrukkar, A. N., Shet, T. M., Patil, A. J., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00126 · Cited by 5
Wanchoo, P., Larrison, C., Rosenberg, C. L., Ko, N. Y., Cantril, C. A., Moeller, N., Parikh, R., & Djordjevic, A.-M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0021 · Cited by 4
“performance gaps were identified: (1) selecting optimal treatment, (2) personalizing therapy, (3) monitoring mBC, (4) engaging in effective”
BackgroundNEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Семиглазов, В. Ф., Семиглазов, В. В., Dashyan, G. A., Криворотько, П. В., Иванов, В. Г., Жильцова, Е. К., Палтуев, Р. М., Берштейн, Л. М., Semiglazova, Т. Y., Yerechshenko, S. S., et al. (2018) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2018-17-3-11-19 · Cited by 4
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Gluz, O., Kolberg‐Liedtke, C., Marmé, F., & Thill, M. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1126-4247 · Cited by 4
“Paclitaxel is today used preferably in treatment schedules that include weekly paclitaxel [4,31] as the weekly schedule has proved significantly superior to the licensed three-weekly dosage as regards ORR and OS in patients with metastatic breast cancer [32].”
BackgroundAssessing Treatment Response in Metastatic Breast Cancer
Shachar, S. S. (2016) · American Journal of Hematology / Oncology® · Cited by 4
Hurtaud, A., Donnadieu, A. C., Escalup, L., Cottu, P. H., & Baffert, S. (2016) · The Breast · doi:10.1016/j.breast.2016.08.015 · Cited by 4
“logy Assessment, Center for schild, 26 Rue Manin, 75019 So far, there is no gold standard treatment defined for very advanced MBC [6,7].”
Herbrand, A. K., Schmitt, A. M., Briel, M., Diem, S., Ewald, H., Hoogkamer, A., Joerger, M., Cord, K. A. M., Novak, U., Sricharoenchai, S., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000596 · Cited by 5
“5.”
Ju, G., Zhu, R., Zhao, H., Ye, F., Zhang, L., Lin, C., Lu, Y., Zhang, X., Li, N., Xue, P., et al. (2018) · Europe PMC (PubMed Central) · Cited by 6
Zhang, J., Wang, L., Wang, Z., Wang, B., Cao, J., Lv, F., Zhang, S., Shao, Z., & Hu, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18539 · Cited by 4
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer
Rosvig, L., Langkjer, S. T., Knoop, A. S., & Jensen, A. B. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1407495 · Cited by 4
“In this situation, the purpose of treatment will be to ease symptoms in order to maintain or improve quality of life and if possible, to prolong life [2,3].”
BackgroundLin, N. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1427 · Cited by 4
In Response to “Serum Tumor Marker Use in Patients With Advanced Solid Tumors”
Dayyani, F., Morgenstern, D. E., & Holdenrieder, S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009241 · Cited by 4
Rosso, K. J., Ueno, N. T., Woodward, W. A., & Lucci, A. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4337-y · Cited by 4
Stevens, S. X., El-Katateny, E., Addo, I. Y., Street, D. J., Booth, C. M., Shaw, J., Vardy, J. L., & Lourenço, R. D. A. (2025) · Patient · doi:10.1007/s40271-025-00778-y · Cited by 3
“…early stage disease, where adjuvant systemic treatment given for a limited time course aims to increase the proportion of patients cured of their disease, palliative systemic treatments for advanced cancers are usually given indefinitely with the aim of improving quantity and quality of life [32].”
Consensus on precision medicine for metastatic cancers: A report from the MAP
Swanton, C., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., André, F., Roussy, G., Xi, P.-S., & Wohl, W. (2016) · Cited by 3
Self-citationCardoso, F., & Senkus, E. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.226 · Cited by 3
Self-citationRezaee, A., Buck, A. K., Raderer, M., Langsteger, W., & Beheshti, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48567-8.00003-1 · Cited by 5
Артамонова, Е. В., Kovalenko, E. I., Болотина, Л. В., Stenina, M. B., Орлова, Р. В., & Mukhina, M. A. (2020) · Tumors of female reproductive system · doi:10.17650/1994-4098-2020-16-3-37-45 · Cited by 6
Breast Cancer Microenvironment and the Metastatic Process
Sflomos, G., & Brisken, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_5 · Cited by 4
Kolben, T., Bardenhewer, M., Kolben, T. M., Rickerl, L., Degenhardt, T., Mahner, S., Harbeck, N., & Wuerstlein, R. (2019) · Breast Care · doi:10.1159/000504527 · Cited by 4
Self-citationNew Insights into Endocrine Therapy for Young Women with Breast Cancer
Lascio, S. D., & Pagani, O. (2015) · Women s Health · doi:10.2217/whe.15.2 · Cited by 4
Self-citationPertuzumab in HER2-positive breast cancer: a guide to its use
McCormack, P. L. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0267-0 · Cited by 3
Etirinotecan pegol for the treatment of breast cancer
López-Miranda, E., & Cortés, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1154537 · Cited by 3
The 21-gene recurrence score — biology remains at the forefront
Puhalla, S. L., & Davidson, N. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.98 · Cited by 3
Cepparulo, M., & Schmidt, N. (2017) · The Breast · doi:10.1016/j.breast.2016.12.001 · Cited by 3
Meglio, A. D., Lin, N., Freedman, R. A., Barry, W. T., Winer, E. P., & Vaz-Luís, I. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0031 · Cited by 3
Self-citationMetastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management
Senkus, E., & Łacko, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56673-3_49 · Cited by 3
Self-citationFulvestrant in Management of Hormone Receptor-Positive Metastatic Breast Cancer
Shafaee, M. N., & Ellis, M. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0489 · Cited by 5
Li, Y., Xie, Y., Gong, C., Zhao, Y., Zhang, J., Zhang, S., Wang, L., Chen, S., Hu, X., & Wang, B. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s255365 · Cited by 4
Ishitobi, M., Shiba, M., Nakayama, T., Koyama, H., & Tamaki, Y. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.534 · Cited by 2
“Resistance to endocrine therapy was defined as disease relapse while receiving adjuvant endocrine therapy, or relapse within 12 months of completing such therapy (15).”
Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study
Jianna, S., Lingjun, K., Nana, F., Liu, H., & Chongxi, R. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221115356 · Cited by 3
“The overall survival (OS) was approximately 16 to 29 months.(6) For several decades, treatment of metastatic breast cancer has been challenged by lack of reliable therapeutic options.”
BackgroundKadi, M. S., Alhebshi, A. H., Shabkah, A. A., Alzahrani, W. A., Enani, G. N., Samkari, A., Iskanderani, O. F., Saleem, A., Farsi, A., & Trabulsi, N. H. (2023) · Cureus · doi:10.7759/cureus.42389 · Cited by 5
Daguenet, É., Jmour, O., Vallard, A., Guy, J., Jacquin, J.-P., Méry, B., & Magné, N. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.01.012 · Cited by 5
Tsigginou, A., Vlachopoulos, F., Arzimanoglou, I. I., Zagouri, F., & Dimitrakakis, C. (2015) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-015-0037-y · Cited by 2
Bielčiková, Z. (2016) · Onkologie · doi:10.36290/xon.2016.037 · Cited by 2
Benbrahim, Z., Berrada, A., Amaadour, L., Mrabet, F. Z., Elfatemi, H., Elfakir, S., Mellas, N., & Arifi, S. (2017) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2017.09.005 · Cited by 2
Management of BRCA mutation carriers
Paris, I., Giorgio, D. D., Palluzzi, E., Garganese, G., Terribile, D. A., Fragomeni, S. M., D’Archi, S., Scambia, G., & Masetti, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.01.23 · Cited by 2
Yamashiro, H., Sawaki, M., Masuda, N., Okumura, Y., Takano, T., Tokunaga, E., Saito, T., Sagara, Y., Yamazaki, K., Kawaguchi, Y., et al. (2018) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223418786243 · Cited by 2
Attai, D. J. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00875 · Cited by 2
T-DM1 for advanced breast cancer after multi-anti-HER2-target therapy: a case report
Sun, L., Gan, L., & Wang, T. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-70 · Cited by 2
“According to the recommendation of several international guidelines, anti-HER2 drugs should be contained not only in neoadjuvant or adjuvant therapy but also in salvage treatment (7,8).”
MethodMale Breast Cancer: Clinical, Demographical, and Pathological Features in a Cohort of 41 Patients
Köşeci, T., Haksöyler, V., Olgun, P., Koyuncu, M. B., Duman, B. B., & Çil, T. (2021) · Cureus · doi:10.7759/cureus.17812 · Cited by 2
“In contrast, the rate of human epidermal growth factor receptor 2 (HER2) positivity in MBC patients is lower than that in female breast cancer patients [4,5].”
BackgroundMetastatic disease of the breast and local recurrence
Verrill, M. W. (2019) · Surgery (Oxford) · doi:10.1016/j.mpsur.2019.01.013 · Cited by 2
Xia, D., Wang, H., Wang, R., Liu, C., & Xu, J. (2018) · Medicine · doi:10.1097/md.0000000000011115 · Cited by 2
“years of adjuvant ET or disease progression more than 6 months after ET or secondary resistance.([7]) Preclinical studies have documented that patients who demonstrate resistance to one”
BackgroundVazquez, L., Arnaud, A., Grenier, J., & Debourdeau, P. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.01.007 · Cited by 2
RetractedZohora, F. T., & Rabbi, M. F. (2018) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20183232 · Cited by 1
“Use of drugs like anthracyclines or, taxenes may develop a potential chance of resistance that limit the second line chemotherapy to a small number of non-cross resistant regimen.(44) Two nontaxane mitotic inhibitors-eribulin and ixabepilone are considered as alternative chemotherapeutics with improved mortality rate.”
BackgroundAkdağ, G., Doğan, A., Yildirim, S., Kınıkoğlu, O., Mokresh, M. E., Alomarı, O., Türkoğlu, E., Işık, D., Sürmeli, H., Başoğlu, T., et al. (2024) · Cureus · doi:10.7759/cureus.63362 · Cited by 1
“In aBC, international practice guidelines have refrained from expressing a preference for a specific agent [10-12].”
BackgroundÖner, İ., Türkel, A., Anık, H., Arslan, Ü. Y., & Karaçin, C. (2024) · Future Oncology · doi:10.1080/14796694.2024.2432850 · Cited by 2
CDK inhibitors in hormone receptor positive advanced breast cancer
Aktaş, B. (2015) · Marmara medical journal · doi:10.5472/mmj.77406 · Cited by 2
“Several types of single-agent or combined endocrine treatment modalities are available achieving most of these goals and represent the standard of care for the first line therapy [3].”
BackgroundMetastatic disease of the breast and local recurrence
Verrill, M. W. (2016) · Surgery (Oxford) · doi:10.1016/j.mpsur.2015.11.001 · Cited by 2
New prospects in the use of Kadcyla® in breast cancer
Dashyan, G. A., Семиглазов, В. Ф., Криворотько, П. В., Палтуев, Р. М., Топузов, Э. Э., Semiglazova, T. Y., Жильцова, Е. К., Донских, Р. В., Табагуа, Т. Т., & Apollonova, V. S. (2015) · Tumors of female reproductive system · doi:10.17650/1994-4098-2015-11-4-46-52 · Cited by 1
Breast cancer a chronic disease? The Anti-HER2 therapy
Pospíšková, M., & Kohoutek, M. (2016) · Klinická farmakologie a farmacie · doi:10.36290/far.2016.032 · Cited by 1
Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report
Kawasaki, K., Hamamoto, Y., Suzuki, T., Hirata, K., Sukawa, Y., Kasuga, A., Hayashi, Y., Takaishi, H., Kameyama, K., & Kanai∥, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.6601 · Cited by 1
“For breast cancer, the NCCN, the American Society of Clinical Oncology, and the European Society for Medical Oncology guidelines all recommend rebiopsy of the metastasis (1,15,16).”
Current treatment of HER 2+ metastatic breast cancer
Burcombe, R. J. (2017) · British Journal of Nursing · doi:10.12968/bjon.2017.26.sup16a.s7 · Cited by 1
Evaluating health and well-being interventions for patients with secondary breast cancer
Gaskell, C., Foy, S., Fox, R., Daniel, B., Miles, J., Hindmarch, S., & Farrell, C. (2017) · Cancer Nursing Practice · doi:10.7748/cnp.2017.e1457 · Cited by 1
Wang, Y., Zhao, Y., Liu, S., Tang, W., Gao, H., Zheng, X., Hong, S., & Wang, S. (2017) · Medicine · doi:10.1097/md.0000000000008203 · Cited by 1
“Therefore, MAST was still the potential routine surgical approach for NMBC patients.([15]) For patients who received preoperative-therapy, pathological complete remission (pCR) was a validated prediction model.”
MethodTremblay, G., Majethia, U., Kontoudis, I., & de Rosendo, J. (2015) · Journal of health economics and outcomes research · doi:10.36469/9834 · Cited by 1
He, L., She, C., Jiang, S., Qi, Z., Deng, Z., Ji, L., Cui, Y., & Wu, J. (2024) · Biology Direct · doi:10.1186/s13062-024-00464-3 · Cited by 1
“The HR + endocrine therapy drug resistance standards for breast cancer were according to the ESO-ESMO Second Edition International Consensus Guidelines for Advanced breast cancer [35].”
MethodProstate cancer is not breast cancer
Venniyoor, A. (2016) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.176980 · Cited by 1
“This is reflected in the current guidelines for management of metastatic breast cancer (MBC),[1] where the bar for aggressive treatment has been further raised recently by defining “visceral crises” as not the mere presence of visceral metastasis, but metastasis to visceral organs compromising organ function.”
BackgroundPatient-reported outcomes in advanced breast cancer: inside the label and approval documents
Hao, Y., Krohe, M., Mazar, I., Galipeau, N., Foley, C., GLOBE, D. R., Turner‐Bowker, D. M., & Shields, A. L. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2016.1174068 · Cited by 2
“oncology in recent years [16], this review, as also reported by Efficace (2015) [25] and Bylicki (2015) [22], suggests that there is much room for improvement in how sponsors develop, implement, and report PRO measurement strate-”
ResultA Review of Local and Systemic Therapy in Breast Cancer
Aydıner, A., Şen, F., Karanlık, H., Aslay, I., Dinçer, M., & İğci, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-26012-9_44 · Cited by 1
Electrochemotherapy for Breast Cancer
Campana, L. G., Galuppo, S., Marconato, R., & Matthiessen, L. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-26779-1_126-1 · Cited by 1
Martiniuc, A., Dumitraşcu, T., Pavel, M., & Stroescu, C. (2017) · Chirurgia · doi:10.21614/chirurgia.112.2.165 · Cited by 1
“International consensus guidelines now recognize that surgery can be recommended in a subgroup of patients (7,8).”
BackgroundDefining what matters most to patients
Coleby, T. (2017) · British Journal of Nursing · doi:10.12968/bjon.2017.26.sup16a.s15 · Cited by 2
Tabouret-Viaud, C., Mainta, I., Garibotto, V., Botsikas, D., Delattre, B. M. A., & Ratib, O. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-68517-5_14 · Cited by 1
Фролова, М. А., Glazkova, E. B., & Stenina, M. B. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-10-158-160 · Cited by 1
Kikawa, Y., Kotake, T., Kajiwara, Y., Hashimoto, K., Yamashiro, H., Ohtani, S., Takao, S., & Toi, M. (2019) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223418825135 · Cited by 1
Prevention Strategies for Brain Metastasis
Soffietti, R., Pellerino, A., & Rudà, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-23417-1_31 · Cited by 1
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
Álvarez, I., Bezares, S., Dalmau, E., García-Martínez, E., García-Sáenz, J. Á., Gil‐Gil, M., de Dueñas, E. M., Ribelles, N., & Santaballa, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02269-7 · Cited by 2
Untch, M., Würstlein, R., Lüftner, D., Haidinger, R., Fasching, P. A., Augustin, D., Briest, S., Ettl, J., Forster, F. M. C., Kurbacher, C. M., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1139-9380 · Cited by 3
Self-citationKuba, S., Moriuchi, H., Yamanouchi, K., Shibata, K., Yano, H., Oikawa, M., Maeda, S., Meng, X., Morita, M., Hatachi, T., et al. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100739 · Cited by 2
Фролова, М. А., Глазкова, Е. В., & Stenina, M. B. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-9-148-153 · Cited by 1
Growth dynamics of breast cancer stem cells: effects of self-feedback and EMT mechanisms
Pang, L., Liu, S., Zhao, Z., Tian, T., Zhang, X., & Li, Q. (2022) · Theory in Biosciences · doi:10.1007/s12064-022-00374-w · Cited by 1
“Hence, advanced breast cancer remains an incurable disease by current treatment strategies (Cardoso et al. 2014).”
BackgroundThe need for post-mastectomy radiotherapy in patients with IBC
Ares, G. J. R., Ciruelos, E., & Manso, L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.13-c1 · Cited by 1
Herbrand, A. K., Schmitt, A., Briel, M., Diem, S., Ewald, H., Hoogkamer, A., Joerger, M., Cord, K. A. M., Novak, U., Sricharoenchai, S., et al. (2019) · medRxiv · doi:10.1101/19003152 · Cited by 1
Predictors of Endocrine Resistance in a Cohort of Mexican Breast Cancer PatientsPreprint
González-Ruíz, J., Terry, M. B., Cabrera‐Galeana, P., Monroy-Chargoy, A., Horowitz, C. R., Bickell, N. A., García-Cuellar, C. M., Ramírez, A., Bargalló, E., Díaz‐Chávez, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4414887/v1 · Cited by 1
The Role of Adjuvant Systemic Therapy
Pluchinotta, A. M., Ghiotto, C., & Baretta, Z. (2015) · Springer eBooks · doi:10.1007/978-3-319-15907-2_18
Managing Breast Cancer in Young Women
Habib, J. G., & Azim, H. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-17278-1_2
Bairamov, E. T., Белоногов, А. A., Брусничкина, В. A., Булах, А. A., Бяхов, М. A., Николаевич, Г. С., Eremeev, G. G., Жуков, Н. В., Жукова, Л. Г., Когония, Л. М., et al. (2015) · Research and Practical Medicine Journal · doi:10.17709/2409-2231-2015-2-2-14
Actualidades del tratamiento del cáncer de mama metastásico HER2-positivo
Matus-Santos, J., Arce-Salinas, C., Flores-Díaz, D., Reynoso‐Noverón, N., Villarreal-Garza, C. M., Alvarado-Miranda, A., Lara-Medina, F. U., & Mohar, A. (2015) · Revista Mexicana de Mastología
Molecular Analysis of Breast Cancer Transcriptomes, Genomes, and Circulating Tumor DNA
Olsson, E. (2015) · Lund University Publications (Lund University)
The need for post-mastectomy radiotherapy in patients with IBC
Tryfonidis, K., Senkus, E., Cardoso, M. J., & Cardoso, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.13-c2
Self-citationBevacizumab: the phoenix of breast oncology?
West, J. (2015)
S-1 versus taxanes for HER2-negative metastatic breast cancer
Martín, M., & López‐Tarruella, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00470-2
Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
Rauthan, A., Dattatreya, P. S., Singhal, M. K., Prabu, R., Naik, S., & Kukreja, A. (2015) · Asian Journal of Oncology · doi:10.4103/2454-6798.173299
“untreated HER2+ mBC based on the OS benefit demonstrated in CLEOPATRA study.[45]”
MethodBorisov, K. E., & Sakaeva, D. (2015) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20154578-86
Changing paradigms in the treatment of hormone-receptor positive advanced breast cancer
Filippi, R., & Montemurro, F. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1174213
“For these reasons, guidelines recommend to consider endocrine therapy as a default option in a hormone-receptor positive metastatic breast cancer patient when there is ‘no concern or proof of endocrine resistance or there is disease needing a fast response’.[5] In general, adding a biologic to all patients with hormon…”
BackgroundW zaawansowanym raku piersi należy kontynuować chemioterapię do czasu progresji
Duchnowska, R. (2016) · Nowotwory Journal of Oncology · doi:10.5603/njo.2016.0007
Komguem, L., Guilbert, P., Doublier, M., & Guillemin, F. H. (2016) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2016.06.007
Altundağ, K. (2016) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2016.09.001
Pogoda, K., Niwińska, A., Jagiełło-Gruszfeld, A., Górniak, A., Giermek, J., & Nowecki, Z. (2015) · Oncology in Clinical Practice
Czartoryska-Arłukowicz, B. (2015) · Nowotwory Journal of Oncology · doi:10.5603/njo.2015.0029
“Podsumowanie Określenie optymalnego postępowania u chorych na zaawansowanego HER2-dodatniego raka piersi po wystąpieniu przerzutów do mózgu na podstawie opublikowanych dotychczas badań jest trudne, niemniej jednak kontynuacja leczenia anty-HER2 po wystąpieniu progresji choroby (w tym w przypadku: wystąpienia przerzutó…”
Duchnowska, R. (2017) · Nowotwory Journal of Oncology · doi:10.5603/njo.2016.0073
Therapieziele der neoadjuvanten Therapie – Präferenzen von Patientinnen mit frühem Mammakarzinom
Thill, M., Pisa, G., & Isbary, G. (2017) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/s-0043-105669
“Aber darüber hinaus sind neoadjuvante und adjuvante Chemotherapie heute gleichwertige alternative Therapieoptionen in der Behandlung des frühen Mammakarzinoms [1, 2, 6, 7].”
BackgroundInfluentialOrlando, L., & Cinieri, S. (2017) · Future Oncology · doi:10.2217/fon-2017-0101
Farhat, F. S., Kattan, J. G., Chahine, G. Y., Makdessi, J., Bitar, N., & Ghosn, M. G. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30797-3
Артамонова, Е. В. (2017) · Tumors of female reproductive system · doi:10.17650/1994-4098-2017-13-3-28-40
Improving patient care: expert nursing and service development
Ryan, C. (2017) · British Journal of Nursing · doi:10.12968/bjon.2017.26.sup16a.s21
Treatment of Advanced Disease: Guidelines
Andre, R., Volovăț, S. R., & Cardoso, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_44
Self-citation
Metadata
- Authors
- Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
- Affiliations
- Centro Champalimaud (PT)
- European School of Oncology (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Gdańsk Medical University (PL)
- Clinique de Genolier (CH)
- Institut Gustave Roussy (FR)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Karolinska University Hospital (SE)
- Fondazione Sandro Pitigliani (IT)
- Duke University (US)
- Champalimaud Foundation (PT)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Peter MacCallum Cancer Centre (AU)
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Université Pierre-et-Marie-Curie (FR)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- The University of Sydney (AU)
- Sheba Medical Center (IL)
- Dana-Farber Cancer Institute (US)
- University of Michigan (US)
- Europa Donna (GE)
- Istituto Oncologico della Svizzera Italiana (CH)
- Centre Jean Perrin (FR)
- Institut Jules Bordet (BE)
- University of California, San Francisco (US)
- Indiana University (US)
- Martin Luther University Halle-Wittenberg (DE)
- Cardiff and Vale University Health Board (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cardoso, F.
- ORCID
- Cardoso, F.
- Costa, A.
- Norton, L.
- Senkus, E.
- Aapro, M.
- André, F.
- Barrios, C.H.
- Bergh, J.
- Biganzoli, L.
- Cardoso, M.J.
- Fallowfield, L.
- Francis, P.
- Gelmon, K.
- Giordano, S.H.
- Gligorov, J.
- Harbeck, N.
- Houssami, N.
- Hudis, C.
- Kaufman, B.
- Krop, I.
- Pagani, O.
- Partridge, A.
- Penault-Llorca, F.
- Piccart, M.J.
- Rugo, H.
- Sledge, G.
- Thomssen, C.
- Vorobiof, D.
- Vrieling, C.
- Xu, B.
- Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1871-1888
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4176456
- OpenAlex
- W2127287298
- Cited by
- 540
- References
- 143
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
- MeSH terms
- Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.